Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cytokine-induced killer cells (Kunming Medical University)
- Development stage
- Unknown
- Lead developer
- Kunming Medical University
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous cytokine-induced killer (CIK) cells are an adoptive cell therapy being investigated by Kunming Medical University for the treatment of advanced adenocarcinoma non-small cell lung cancer (NSCLC). CIK cells are a heterogeneous population of immune effector cells, predominantly CD3+CD56+ T cells, generated by the ex vivo expansion of a patient's own peripheral blood mononuclear cells (PBMCs) in the presence of interferon-gamma (IFN-γ), interleukin-2 (IL-2), and anti-CD3 antibodies. These cells exhibit potent, non-MHC-restricted cytolytic activity against a broad spectrum of tumor cells. In clinical trials, this therapy is administered via intravenous infusion, often in combination with the EGFR tyrosine kinase inhibitor gefitinib, to enhance anti-tumor efficacy and improve survival outcomes in patients who have failed prior chemotherapy.
- Other names
- CIK cellsAutologous CIK cell immunotherapyAutologous CIK transfusionCytokine-induced killer cells
Beyond the preview
Go deeper on autologous cytokine-induced killer cells (Kunming Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cytokine-induced killer cells (Kunming Medical University).